Literature DB >> 10826417

Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction.

G T Trevisani1, N H Hyman, J M Church.   

Abstract

BACKGROUND: Ogilvie's syndrome, or acute colonic pseudo-obstruction, is a common and relatively dangerous condition. If left untreated, it may cause ischemic necrosis and colonic perforation, with a mortality rate as high as 50 percent. Neostigmine enhances excitatory parasympathetic activity by competing with acetylcholine for attachment to acetylcholinesterase at sites of cholinergic transmission and enhancing cholinergic action. We hypothesized that neostigmine would restore peristalsis in patients with acute colonic pseudo-obstruction.
METHODS: Twenty-eight patients at Fletcher Allen Health Care and The Cleveland Clinic Foundation were treated for acute colonic pseudo-obstruction with neostigmine 2.5 mg IV over 3 minutes while being monitored with telemetry. Mechanical obstruction had been excluded.
RESULTS: Complete clinical resolution of large bowel distention occurred in 26 of the 28 patients. Time to pass flatus varied from 30 seconds to 10 minutes after administration of neostigmine. No adverse effects or complications were noted. Of the two patients who did not resolve, one had a sigmoid cancer that required resection and one patient died from multiorgan failure.
CONCLUSION: This study supports the theory that acute colonic pseudo-obstruction is the result of excessive parasympathetic suppression rather than sympathetic overactivity. We have shown that neostigmine is a safe and effective treatment for acute colonic pseudo-obstruction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10826417     DOI: 10.1007/bf02235569

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  18 in total

Review 1.  Acute colonic pseudoobstruction.

Authors:  Michael D Saunders
Journal:  Curr Gastroenterol Rep       Date:  2004-10

2.  Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial.

Authors:  S N Sgouros; J Vlachogiannakos; K Vassiliadis; C Bergele; G Stefanidis; H Nastos; A Avgerinos; A Mantides
Journal:  Gut       Date:  2005-11-23       Impact factor: 23.059

3.  Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient.

Authors:  Chang Hwan Park; Young Eun Joo; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew; Sei Jong Kim
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

Review 4.  Acute colonic pseudoobstruction.

Authors:  Allen P Chudzinski; Earl V Thompson; Jennifer M Ayscue
Journal:  Clin Colon Rectal Surg       Date:  2015-06

Review 5.  [Perioperative protection of the gastrointestinal tract].

Authors:  K Weismüller; S Hofer; M A Weigand
Journal:  Anaesthesist       Date:  2012-08       Impact factor: 1.041

6.  Acute Colonic Pseudo-Obstruction (Ogilvie's Syndrome).

Authors:  Jan Tack
Journal:  Curr Treat Options Gastroenterol       Date:  2006-07

7.  Acute intestinal pseudo-obstruction (Ogilvie's syndrome).

Authors:  Nell Maloney; H David Vargas
Journal:  Clin Colon Rectal Surg       Date:  2005-05

8.  Advances and challenges in the management of acute colonic pseudo-obstruction (ogilvie syndrome).

Authors:  Arpana Jain; H David Vargas
Journal:  Clin Colon Rectal Surg       Date:  2012-03

9.  Ogilvie's syndrome following caesarean section.

Authors:  Adeyinka Oluseun Latunde-Dada; Djavid I Alleemudder; Daniel P Webster
Journal:  BMJ Case Rep       Date:  2013-06-19

10.  Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility.

Authors:  J Broad; V W S Kung; G Boundouki; Q Aziz; J H De Maeyer; C H Knowles; G J Sanger
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.